NCT05333679 is a NA clinical trial of UTRA in Risk Reduction, sponsored by University of California, San Francisco.

Who is sponsoring NCT05333679?

NCT05333679 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT05333679?

Interventions in NCT05333679: UTRA, UTRA feedback.

What condition does NCT05333679 study?

NCT05333679 studies Risk Reduction.

Is NCT05333679 still recruiting?

NCT05333679 is currently active, enrolled. Last updated 27 October 2025.

Last reviewed 2025-10-27 · How we verify

NCT05333679

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)

Active, enrolled NA Last updated 27 October 2025

What this trial tests

NA trial testing UTRA in Risk Reduction in 200 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 March 2022

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	University of California, San Francisco
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	200
Start date	2 March 2022
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across South Africa

Drugs / interventions tested

UTRA
UTRA feedback

Conditions studied

Risk Reduction — all drugs for Risk Reduction →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Risk Reduction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

ART is given to people living with HIV in order to suppress the virus, resulting in improved health for the individual and decreased transmission of the virus to others. Success of ART is dependent on adherence. Currently, adherence is assessed by asking patients directly and then confirming with a viral load test, which is expensive and is often only done when the viral load is already raised. Therefore there is a need to find a method to detect problems with adherence early before the viral load rises. A urine-based test was recently developed, called UTRA (urine tenofovir rapid assay). This test can give clinic staff immediate results about a person's adherence to the antiretroviral medication Tenofovir (TDF). The study will compare the results of this urine test to drug levels found in blood, self-reported adherence and pharmacy collection records to see if this test can be used as part of routine care in ART clinics. If the test is effective it would allow clinic staff to identify people with adherence difficulties early and give them the necessary support before their viral load rises.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial.
van Zyl GU, Decloedt E, Jennings L, Kellermann T, et al · · 2025 · PMID 40578842 · DOI 10.1093/cid/ciaf337

Verify or expand the search:

Other recruiting trials for Risk Reduction

Currently open trials in the same condition.

NCT06529913 — Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases · NA · recruiting
NCT06446427 — The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care · NA · active not recruiting
NCT06611462 — STRONG for Surgery & Strong for Life - Intensive Prehabilitation for Risk Reduction in Ventral Hernia Repair · NA · recruiting
NCT06001892 — Tennessee Youth Prepared for Success · NA · active not recruiting
NCT05712252 — Fall, Fracture and Frailty · active not recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05333679 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 27 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05333679.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing